|
1
|
Frommeyer G and Eckardt L: Drug-induced
proarrhythmia: Risk factors and electrophysiological mechanisms.
Nat Rev Cardiol. 13:36–47. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Vicente J, Zusterzeel R, Johannesen L,
Mason J, Sager P, Patel V, Matta MK, Li ZH, Liu J, Garnett C, et
al: Mechanistic model-informed proarrhythmic risk assessment of
drugs: Review of the ‘CiPA’ initiative and design of a prospective
clinical validation study. Clin Pharmacol Ther. 103:54–66.
2018.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Niemeijer MN, van den Berg ME, Eijgelsheim
M, Rijnbeek PR and Stricker BH: Pharmacogenetics of drug-induced QT
interval prolongation: An update. Drug Saf. 38:855–867.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
El-Sherif N and Turitto G: Electrolyte
disorders and arrhythmogenesis. Cardiol J. 18:233–245.
2011.PubMed/NCBI
|
|
5
|
Shah RR: Drugs, QT interval prolongation
and ICH E14: The need to get it right. Drug Saf. 28:115–125.
2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Darpo B and Ferber G: The new S7B/E14
question and answer draft guidance for industry: Contents and
commentary. J Clin Pharmacol. 61:1261–1273. 2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Vargas HM, Rolf MG, Wisialowski TA,
Achanzar W, Bahinski A, Bass A, Benson CT, Chaudhary KW, Couvreur
N, Dota C, et al: Time for a fully integrated nonclinical-clinical
risk assessment to streamline QT prolongation liability
determinations: A pharma industry perspective. Clin Pharmacol Ther.
109:310–318. 2021.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Sanguinetti MC and Mitcheson JS:
Predicting drug-hERG channel interactions that cause acquired long
QT syndrome. Trends Pharmacol Sci. 26:119–124. 2005.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gintant G, Sager PT and Stockbridge N:
Evolution of strategies to improve preclinical cardiac safety
testing. Nat Rev Drug Discov. 15:457–471. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang S, Zhou Z, Gong Q, Makielski JC and
January CT: Mechanism of block and identification of the verapamil
binding domain to HERG potassium channels. Circ Res. 84:989–998.
1999.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fenichel RR, Malik M, Antzelevitch C,
Sanguinetti M, Roden DM, Priori SG, Ruskin JN, Lipicky RJ and
Cantilena LR: Independent Academic Task Force. Drug-induced
torsades de pointes and implications for drug development. J
Cardiovasc Electrophysiol. 15:475–495. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yim DS: Five years of the CiPA project
(2013-2018): What did we learn? Transl Clin Pharmacol. 26:145–149.
2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Park JS, Jeon JY, Yang JH and Kim MG:
Introduction to in silico model for proarrhythmic risk assessment
under the CiPA initiative. Transl Clin Pharmacol. 27:12–18.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wallis R, Benson C, Darpo B, Gintant G,
Kanda Y, Prasad K, Strauss DG and Valentin JP: CiPA challenges and
opportunities from a non-clinical, clinical and regulatory
perspectives. An overview of the safety pharmacology scientific
discussion. J Pharmacol Toxicol Methods. 93:15–25. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Roden DM: Predicting drug-induced QT
prolongation and torsades de pointes. J Physiol. 594:2459–2468.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
16
|
Crestani T, Steichen C, Neri E, Rodrigues
M, Fonseca-Alaniz MH, Ormrod B, Holt MR, Pandey P, Harding S, Ehler
E and Krieger JE: Electrical stimulation applied during
differentiation drives the hiPSC-CMs towards a mature cardiac
conduction-like cells. Biochem Biophys Res Commun. 533:376–382.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ando H, Yoshinaga T, Yamamoto W, Asakura
K, Uda T, Taniguchi T, Ojima A, Shinkyo R, Kikuchi K, Osada T, et
al: A new paradigm for drug-induced torsadogenic risk assessment
using human iPS cell-derived cardiomyocytes. J Pharmacol Toxicol
Methods. 84:111–127. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huo J, Wei F, Cai C, Lyn-Cook B and Pang
L: Sex-related differences in drug-induced QT prolongation and
torsades de Pointes: A new model system with human iPSC-CMs.
Toxicol Sci. 167:360–374. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
da Rocha AM, Creech J, Thonn E, Mironov S
and Herron TJ: Detection of drug-induced torsades de Pointes
arrhythmia mechanisms using hiPSC-CM syncytial monolayers in a
high-throughput screening voltage sensitive dye assay. Toxicol Sci.
173:402–415. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Raphel F, De Korte T, Lombardi D, Braam S
and Gerbeau JF: A greedy classifier optimization strategy to assess
ion channel blocking activity and pro-arrhythmia in
hiPSC-cardiomyocytes. PLoS Compute Biol.
16(e1008203)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Blinova K, Dang Q, Millard D, Smith G,
Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, et al:
International multisite study of human-induced pluripotent stem
cell-derived cardiomyocytes for drug proarrhythmic potential
assessment. Cell Rep. 24:3582–3592. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tu JV: Advantages and disadvantages of
using artificial neural networks versus logistic regression for
predicting medical outcomes. J Clin Epidemiol. 49:1225–1231.
1996.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Heo J, Yoon JG, Park H, Kim YD, Nam HS and
Heo JH: Machine learning-based model for prediction of outcomes in
acute stroke. Stroke. 50:1263–1265. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sherazi SW, Bae JW and Lee JY: A soft
voting ensemble classifier for early prediction and diagnosis of
occurrences of major adverse cardiovascular events for STEMI and
NSTEMI during 2-year follow-up in patients with acute coronary
syndrome. PLoS One. 16(e0249338)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Asakura K, Hayashi S, Ojima A, Taniguchi
T, Miyamoto N, Nakamori C, Nagasawa C, Kitamura T, Osada T, Honda
Y, et al: Improvement of acquisition and analysis methods in
multi-electrode array experiments with iPS cell-de rived
cardiomyocytes. J Pharmacol Toxicol Methods. 75:17–26.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Gerds TA, Cai T and Schumacher M: The
performance of risk prediction models. Biom J. 50:457–479.
2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Pencina MJ and D'Agostino RB Sr:
Evaluating discrimination of risk prediction models: The C
statistic. JAMA. 314:1063–1064. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Alba AC, Agoritsas T, Walsh M, Hanna S,
Iorio A, Devereaux PJ, McGinn T and Guyatt G: Discrimination and
calibration of clinical prediction models: Users' guides to the
medical literature. JAMA. 318:1377–1384. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ziegler R, Häusermann F, Kirchner S and
Polonchuk L: Cardiac safety of kinase inhibitors-improving
understanding and prediction of liabilities in drug discovery using
human stem cell-derived models. Front Cardiovasc Med.
8(639824)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Harary I and Farley B: In vitro studies of
single isolated beating heart cells. Science. 131:1674–1675.
1960.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Price PS, Keenan RE and Swartout JC:
Characterizing interspecies uncertainty using data from studies of
anti-neoplastic agents in animals and humans. Toxicol Appl
Pharmacol. 233:64–70. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sheng CC, Amiri-Kordestani L, Palmby T,
Force T, Hong CC, Wu JC, Croce K, Kim G and Moslehi J: 21st century
cardio-oncology: Identifying cardiac safety signals in the era of
personalized medicine. JACC Basic Transl Sci. 1:386–398.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Haraguchi Y, Ohtsuki A, Oka T and Shimizu
T: Electrophysiological analysis of mammalian cells expressing hERG
using automated 384-well-patch-clamp. BMC Pharmacol Toxicol.
16(39)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Higa A, Hoshi H, Yanagisawa Y, Ito E,
Morisawa G, Imai JI, Watanabe S and Takagi M: Evaluation system for
arrhythmogenic potential of drugs using human-induced pluripotent
stem cell-derived cardiomyocytes and gene expression analysis. J
Toxicol Sci. 42:755–761. 2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Abassi YA, Xi B, Li N, Ouyang W, Seiler A,
Watzele M, Kettenhofen R, Bohlen H, Ehlich A, Kolossov E, et al:
Dynamic monitoring of beating periodicity of stem cell-derived
cardiomyocytes as a predictive tool for preclinical safety
assessment. Br J Pharmacol. 165:1424–1441. 2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wang SY, Wang XJ and Ma J: Progress in
real time xCELLigence analysis system on drug cardiotoxicity
screening. Chin J Pharmacol Toxicol,. 27:908–912. 2013.
|
|
37
|
Yue Peng, Ying BB, He Min and Yang
ChaoWen: Study on hepatotoxicity of different doses of cisplatin in
rats. J Toxico l,. 33:302–306. 2019.
|
|
38
|
Marcu IC, Illaste A, Heuking P, Jaconi ME
and Ullrich ND: Functional characterization and comparison of
intercellular communication in stem cell-derived cardiomyocytes.
Stem Cells. 33:2208–2218. 2015.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Clements M: Multielectrode array (MEA)
assay for profiling electrophysiological drug effects in human stem
cell-derived cardiomyocytes. Curr Protoc Toxicol.
68:22.24.21–22.24.32. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
Halbach M, Egert U, Hescheler J and Banach
K: Estimation of action potential changes from field potential
recordings in multicellular mouse cardiac myocyte cultures. Cell
Physiol Biochem. 13:271–284. 2003.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sharifi M, Buzatu D, Harris S and Wilkes
J: Development of models for predicting Torsade de Pointes cardiac
arrhythmias using perceptron neural networks. BMC Bioinformatics.
18 (Suppl 4)(S497)2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Liu H, Ji M, Luo X, Shen J, Huang X, Hua
W, Jiang H and Chen K: New p-methylsulfonamido phenylethylamine
analogues as class III antiarrhythmic agents: Design, synthesis,
biological assay, and 3D-QSAR analysis. J Med Chem. 45:2953–2969.
2002.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chamberlain AM, Boyd CM, Manemann SM,
Dunlay SM, Gerber Y, Killian JM, Weston SA and Roger VL: Risk
factors for heart failure in the community: Differences by age and
ejection fraction. Am J Med. 133:e237–e248. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Belkin M, Hsu D, Ma S and Mandal S:
Reconciling modern machine-learning practice and the classical
bias-variance trade-off. Proc Natl Acad Sci USA. 116:15849–15854.
2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Hatwell J, Gaber MM and Atif Azad RM:
Ada-WHIPS: Explaining AdaBoost classification with applications in
the health sciences. BMC Med Inform Decis Mak.
20(250)2020.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kanda Y, Yamazaki D, Osada T, Yoshinaga T
and Sawada K: Development of torsadogenic risk assessment using
human induced pluripotent stem cell-derived cardiomyocytes: Japan
iPS cardiac safety assessment (JiCSA) update. J Pharmacol Sci.
138:233–239. 2018.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Aktas MK, Shah AH and Akiyama T:
Dofetilide-induced long QT and torsades de pointes. Ann Noninvasive
Electrocardiol. 12:197–202. 2007.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Jaiswal A and Goldbarg S: Dofetilide
induced torsade de pointes: Mechanism, risk factors and management
strategies. Indian Heart J. 66:640–648. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Thomine S, Zimmerman S, Duijn BV,
Barbier-Brygoo H and Guern J: Calcium channel antagonists induce
direct inhibition of the outward rectifying potassium channel in
tobacco protoplasts. FEBS Lett. 340:45–50. 1994.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Duncan RS, Ridley JM, Dempsey CE, Leishman
DJ, Leaney JL, Hancox JC and Witchel HJ: Erythromycin block of the
HERG K+ channel: Accessibility to F656 and Y652. Biochem Biophys
Res Commun. 341:500–506. 2006.PubMed/NCBI View Article : Google Scholar
|
|
51
|
van Haarst AD, van 't Klooster GA, van
Gerven JM, Schoemaker RC, van Oene JC, Burggraaf J, Coene MC and
Cohen AF: The influence of cisapride and clarithromycin on QT
intervals in healthy volunteers. Clin Pharmacol Ther. 64:542–546.
1998.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Vieweg WV, Hancox JC, Hasnain M, Koneru
JN, Gysel M and Baranchuk A: Clarithromycin, QTc interval
prolongation and torsades de pointes: The need to study case
reports. Ther Adv Infect Dis. 1:121–138. 2013.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Tisdale JE: Drug-induced QT interval
prolongation and torsades de pointes: Role of the pharmacist in
risk assessment, prevention and management. Can Pharm J (Ott).
149:139–152. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lo YC and Kuo CC: Temperature dependence
of the biophysical mechanisms underlying the inhibition and
enhancement effect of amiodarone on hERG channels. Mol Pharmacol.
96:330–344. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shenthar J, Rachaiah JM, Pillai V, Chakali
SS, Balasubramanian V and Chollenhalli Nanjappa M: Incidence of
drug-induced torsades de pointes with intravenous amiodarone.
Indian Heart J. 69:707–713. 2017.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Khan F, Ismail M, Khan Q and Ali Z:
Moxifloxacin-induced QT interval prolongation and torsades de
pointes: A narrative review. Expert Opin Drug Saf. 17:1029–1039.
2018.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Behzadi M, Joukar S and Beik A: Opioids
and cardiac arrhythmia: A literature review. Med Princ Pract.
27:401–414. 2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Kasama M, Furukawa Y, Oguchi T, Hoyano Y
and Chiba S: Effects of low temperature on the chronotropic and
inotropic responses to zatebradine, E-4031 and ver apamil in
isolated perfused dog atria. Jpn J Pharmacol. 78:493–499.
1998.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Saeidnia S, Manayi A and Abdollahi M: From
in vitro Experiments to in vivo and clinical studies; Pros and
cons. Curr Drug Discov Technol. 12:218–224. 2015.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zuppinger C, Gibbons G, Dutta-Passecker P,
Segiser A, Most H and Suter TM: Characterization of cytoskeleton
features and maturation status of cultured human iPSC-derived
cardiomyocytes. Eur J Histochem. 61(2763)2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Cai C, Wang S, Xu YJ, Zhang WL, Tang K,
Ouyang Q, Lai LH and Pei JF: Transfer learning for drug discovery.
J Med Chem. 63:8683–8694. 2020.PubMed/NCBI View Article : Google Scholar
|
